Compare PAGSEG Inc (PAGS) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PAGSEG Inc vs Viatris Inc — how do they compare? PAGSEG Inc trades at $9.74 (market cap $2.68B), while Viatris Inc trades at $17.02 (market cap $20.50B). The key difference: Viatris Inc is far larger — about 7.6× PAGSEG Inc's market cap, and PAGSEG Inc pays the higher dividend (10.86%). Which is the better fit depends on your goals.
| PAGS | VTRS | |
|---|---|---|
Market Cap | $2.68B | $20.50B |
Sector | Technology | Health |
52-Week High | $12.00 | $17.59 |
52-Week Low | $7.75 | $8.74 |
Enterprise Value | $10.42B | $32.71B |
Dividend Yield | 10.86% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PAGS trades at $9.29, up 2.77% with a bullish technical signal. The stock shows attractive valuation metrics with P/E of 6.57 and P/S of 0.68, trading below book value. Recent earnings showed mixed results with Q4 2025 beating expectations but Q1 2026 missing estimates. The company maintains strong profitability with 10.4% net margin and robust cash flow generation of $7.56B from operations in 2025.
Analyst consensus remains strongly bullish with 62.5% buy ratings, though Brazilian macroeconomic risks and competitive pressures warrant monitoring. The stock presents value opportunity with deep discount valuation while benefiting from Brazil's digital banking growth, though execution on credit expansion and funding costs remain key catalysts.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
